Literature DB >> 18546326

Cut-off score of the Mattis Dementia Rating Scale for screening dementia in Parkinson's disease.

Gisela Llebaria1, Javier Pagonabarraga, Jaime Kulisevsky, Carmen García-Sánchez, Berta Pascual-Sedano, Alexandre Gironell, Mercè Martínez-Corral.   

Abstract

The prevalence of dementia in Parkinson's disease (PD) is close to 30%, and its incidence is 4 to 6 times higher than in age-matched general population. PD with dementia (PDD) is mainly characterized by a predominant and progressive frontal-subcortical impairment. The Mattis Dementia Rating Scale (MDRS) is a commonly used screening test that sensitively measures the degree of frontal-subcortical defects. Although the MDRS has been validated as a screening test of cognitive dysfunction in nondemented PD patients (PD-ND), its utility for screening dementia in PD is unknown. In order to validate the MDRS for diagnosis of PDD it was prospectively administered to 92 PD patients (57 PD-ND, 35 PDD) fulfilling UK-PDSBB criteria. Dementia was diagnosed according to DSM-IV-TR and a Clinical Dementia Rating (CDR) scale score >or=1. Univariate, logistic regression, and ROC curve analysis were carried out to measure the discriminative power of MDRS in PDD. Regression analysis showed MDRS total scores to independently differentiate PD-ND from PDD (P < 0.001). Age and education did not predict the presence of dementia. ROC curve analysis showed a cut-off score of <or=123 on the MDRS total scores to yield high sensitivity (92.65%), specificity (91.4%), positive and negative predictive values (PPV 83.3%, NPV 96.4%). A brief version of the MDRS obtained by the addition of the memory, initiation/perseveration, and conceptualization subscores yielded similar discriminant properties. The MDRS has an excellent discriminant ability to diagnose dementia in PD and provides an objective measure to distinguish PD-ND from PDD. (c) 2008 Movement Disorder Society.

Entities:  

Mesh:

Year:  2008        PMID: 18546326     DOI: 10.1002/mds.22173

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  44 in total

Review 1.  Mild cognitive impairment in Parkinson's disease.

Authors:  J G Goldman; I Litvan
Journal:  Minerva Med       Date:  2011-12       Impact factor: 4.806

Review 2.  Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines.

Authors:  Irene Litvan; Jennifer G Goldman; Alexander I Tröster; Ben A Schmand; Daniel Weintraub; Ronald C Petersen; Brit Mollenhauer; Charles H Adler; Karen Marder; Caroline H Williams-Gray; Dag Aarsland; Jaime Kulisevsky; Maria C Rodriguez-Oroz; David J Burn; Roger A Barker; Murat Emre
Journal:  Mov Disord       Date:  2012-01-24       Impact factor: 10.338

3.  Screening for DSM-IV-TR cognitive disorder NOS in Parkinson's disease using the Mattis Dementia Rating Scale.

Authors:  Gregory M Pontone; Justin Palanci; James R Williams; Susan Spear Bassett
Journal:  Int J Geriatr Psychiatry       Date:  2012-05-24       Impact factor: 3.485

Review 4.  Parkinson's disease dementia.

Authors:  Mary J Docherty; David J Burn
Journal:  Curr Neurol Neurosci Rep       Date:  2010-07       Impact factor: 5.081

5.  CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease.

Authors:  A Siderowf; S X Xie; H Hurtig; D Weintraub; J Duda; A Chen-Plotkin; L M Shaw; V Van Deerlin; J Q Trojanowski; C Clark
Journal:  Neurology       Date:  2010-08-18       Impact factor: 9.910

Review 6.  Do CSF Biomarkers Predict Progression to Cognitive Impairment in Parkinson's disease patients? A Systematic Review.

Authors:  Katherine Leaver; Kathleen L Poston
Journal:  Neuropsychol Rev       Date:  2015-12-01       Impact factor: 7.444

7.  A recommended scale for cognitive screening in clinical trials of Parkinson's disease.

Authors:  Kelvin L Chou; Melissa M Amick; Jason Brandt; Richard Camicioli; Karen Frei; Darren Gitelman; Jennifer Goldman; John Growdon; Howard I Hurtig; Bonnie Levin; Irene Litvan; Laura Marsh; Tanya Simuni; Alexander I Tröster; Ergun Y Uc
Journal:  Mov Disord       Date:  2010-11-15       Impact factor: 10.338

8.  The Movement Disorders Society criteria for the diagnosis of Parkinson's disease dementia: their usefulness and limitations in elderly patients.

Authors:  Michèle Kiesmann; Jean-Baptiste Chanson; Julien Godet; Thomas Vogel; Laetitia Schweiger; Saïd Chayer; Georges Kaltenbach
Journal:  J Neurol       Date:  2013-07-09       Impact factor: 4.849

9.  Global cognitive scores do not predict outcome after subthalamic nucleus deep brain stimulation.

Authors:  Darlene Floden; Robyn M Busch; Scott E Cooper; Cynthia S Kubu; Andre G Machado
Journal:  Mov Disord       Date:  2015-07-14       Impact factor: 10.338

10.  Impairment of script comprehension in Lewy body spectrum disorders.

Authors:  Rachel G Gross; Emily Camp; Corey T McMillan; Michael Dreyfuss; Delani Gunawardena; Philip A Cook; Brianna Morgan; Andrew Siderowf; Howard I Hurtig; Matthew B Stern; Murray Grossman
Journal:  Brain Lang       Date:  2013-04-06       Impact factor: 2.381

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.